Last reviewed · How we verify
Meropenem for Injection
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including intra-abdominal infections, Meningitis, Nosocomial pneumonia.
At a glance
| Generic name | Meropenem for Injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Carbapenem antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall degradation and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it effective for serious infections caused by susceptible organisms.
Approved indications
- Serious bacterial infections including intra-abdominal infections
- Meningitis
- Nosocomial pneumonia
- Febrile neutropenia
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Headache
- Seizures
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency (PHASE1)
- Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever (PHASE4)
- Bolus Versus Continuous Infusion of Meropenem (PHASE4)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (PHASE1)
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections (PHASE4)
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |